xanthine has been researched along with Tumor Lysis Syndrome in 4 studies
7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.
9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.
Tumor Lysis Syndrome: A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We experienced three cases of urine xanthine crystals during TLS in patients with hematologic malignancies who received prophylactic febuxostat." | 8.12 | Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome. ( Ashizawa, M; Fujiwara, SI; Hatano, K; Hayatsu, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, S; Matsuoka, S; Minakata, D; Morita, K; Murahashi, R; Nagayama, T; Nakano, H; Nakashima, H; Ohmine, K; Sato, K; Sekiguchi, K; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R; Yoshizawa, T, 2022) |
| "Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, and control of serum uric acid level (S-UA) is most important." | 7.80 | Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. ( Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A, 2014) |
| " We experienced three cases of urine xanthine crystals during TLS in patients with hematologic malignancies who received prophylactic febuxostat." | 4.12 | Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome. ( Ashizawa, M; Fujiwara, SI; Hatano, K; Hayatsu, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, S; Matsuoka, S; Minakata, D; Morita, K; Murahashi, R; Nagayama, T; Nakano, H; Nakashima, H; Ohmine, K; Sato, K; Sekiguchi, K; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R; Yoshizawa, T, 2022) |
| "Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, and control of serum uric acid level (S-UA) is most important." | 3.80 | Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. ( Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A, 2014) |
| " Allopurinal dosage should be reduced or discontinued if xanthine nephropathy is suspected." | 1.34 | Acute renal failure from xanthine nephropathy during management of acute leukemia. ( Bakdash, S; Ellis, D; Krishnamurti, L; LaRosa, C; McMullen, L; Moritz, ML; Wu, HY, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S | 1 |
| Fujiwara, SI | 1 |
| Yoshizawa, T | 1 |
| Hayatsu, K | 1 |
| Sekiguchi, K | 1 |
| Murahashi, R | 1 |
| Nakashima, H | 1 |
| Matsuoka, S | 1 |
| Ikeda, T | 1 |
| Toda, Y | 1 |
| Kawaguchi, S | 1 |
| Nagayama, T | 1 |
| Umino, K | 1 |
| Minakata, D | 1 |
| Nakano, H | 1 |
| Morita, K | 1 |
| Yamasaki, R | 1 |
| Ashizawa, M | 1 |
| Yamamoto, C | 1 |
| Hatano, K | 1 |
| Sato, K | 1 |
| Ohmine, K | 1 |
| Kanda, Y | 1 |
| Takai, M | 1 |
| Yamauchi, T | 1 |
| Ookura, M | 1 |
| Matsuda, Y | 1 |
| Tai, K | 1 |
| Kishi, S | 1 |
| Yoshida, A | 1 |
| Iwasaki, H | 1 |
| Nakamura, T | 1 |
| Ueda, T | 1 |
| Mathisen, MS | 1 |
| LaRosa, C | 1 |
| McMullen, L | 1 |
| Bakdash, S | 1 |
| Ellis, D | 1 |
| Krishnamurti, L | 1 |
| Wu, HY | 1 |
| Moritz, ML | 1 |
4 other studies available for xanthine and Tumor Lysis Syndrome
| Article | Year |
|---|---|
Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome.
Topics: Allopurinol; Hematologic Neoplasms; Humans; Microscopy; Neoplasms; Nephrolithiasis; Tumor Lysis Synd | 2022 |
Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Topics: Aged; Allopurinol; Antineoplastic Agents; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomeru | 2014 |
The tumor lysis syndrome.
Topics: Allopurinol; Drug Costs; Humans; Hypoxanthine; Kidney Diseases; Tumor Lysis Syndrome; Urate Oxidase; | 2011 |
Acute renal failure from xanthine nephropathy during management of acute leukemia.
Topics: Acute Kidney Injury; Allopurinol; Child; Enzyme Inhibitors; Female; Humans; Nephrolithiasis; Precurs | 2007 |